Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1644 1645 1649
This examiner grants 50% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17614865 | AN IMMUNOGENIC SEROTYPE 35B PNEUMOCOCCAL POLYSACCHARIDE-PROTEIN CONJUGATE AND CONJUGATION PROCESS FOR MAKING THE SAME | Final Rejection | Merck Sharp & Dohme LLC |
| 18291827 | MICROORGANISM HAVING WEAKENED ACTIVITY OF LACI FAMILY DNA-BINDING TRANSCRIPTIONAL REGULATOR, AND L-GLUTAMIC ACID PRODUCTION METHOD USING SAME | Non-Final OA | CJ CheilJedang Corporation |
| 18266472 | METHODS AND MATERIALS FOR TREATING CANCER | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 19271861 | GENETICALLY MODIFIED CELLS AND USES THEREOF | Non-Final OA | CARTHERICS PTY LTD |
| 17632023 | Identification and Elimination of HCMV-Infected Cells | Non-Final OA | Cambridge Enterprise Limited |
| 18573131 | HOUSEHOLD AND COMMERCIAL CLEANING ARTICLES WITH MORAXELLA SP. INHIBITING ACTIVITY | Non-Final OA | Carl Freudenberg KG |
| 18276585 | BACTERIAL BIO-CONTROL AGENTS FOR IMPROVING PLANTS' GROWTH, YIELD AND RESISTANCE TO PATHOGENS | Non-Final OA | THE STATE OF ISRAEL, MINISTRY OF AGRICULTURE & RURAL DEVELOPMENT, AGRICULTURAL RESEARCH ORGANIZATION |
| 18184496 | Biocontrol of Fusarium by Endophytic Fungi | Non-Final OA | Board of Trustees of Michigan State University |
| 18661174 | SUBUNIT VACCINE DELIVERY PLATFORM FOR ROBUST HUMORAL AND CELLULAR IMMUNE RESPONSES | Non-Final OA | CORNELL UNIVERSITY |
| 17209712 | ENGINEERED PHAGOCYTIC RECEPTOR COMPOSITIONS AND METHODS OF USE THEREOF | Final Rejection | CREATE Medicines, Inc. |
| 17815729 | THERAPEUTIC COMPOSITIONS CONTAINING BACTERIAL OUTER MEMBRANE VESICLES AND USES THEREOF | Non-Final OA | NUtech Ventures |
| 17745770 | PLASMA KALLIKREIN INHIBITORS AND USES THEREOF FOR TREATING HEREDITARY ANGIOEDEMA ATTACK | Final Rejection | Takeda Pharmaceutical Company Limited |
| 18560020 | COMPOSITIONS AND METHODS FOR TREATING DISEASE | Non-Final OA | MICROBA IP PTY LTD |
| 17794085 | Identification And Synthesis Of Drug Candidates Derived From Human Microbiome Metasecretome Proteins | Non-Final OA | ENTEROME S.A. |
| 18270092 | IMPROVED METHODS TO ENHANCE GASTROINTESTINAL HEALTH | Non-Final OA | ARBIOM SAS |
| 17289519 | COMBINATION TREATMENT WITH ANTI-CD123 ANTIBODY DRUG CONJUGATE AND PARP INHIBITOR | Non-Final OA | Health Research, Inc. |
| 18251474 | USE OF INTERLEUKIN-7 FOR THE TREATMENT OF CORONAVIRUS | Non-Final OA | NeoImmuneTech, Inc. |
| 18296982 | METHODS AND APPARATUSES FOR DETECTING RESPIRATORY INFECTIONS | Non-Final OA | ControlPoint Inc. |
| 17843480 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | Final Rejection | INSTIL BIO (UK) LIMITED |
| 18157027 | RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY | Non-Final OA | Instil Bio, Inc. |
| 17923142 | SINGLE DOMAIN ANTIBODIES BINDING TO SARS-COV-2 SPIKE PROTEIN | Non-Final OA | THE ROSALIND FRANKLIN INSTITUTE |
| 17812800 | Methods for the Manufacture of Proteolytically Processed Polypeptides | Non-Final OA | IPSEN BIOINNOVATION LIMITED |
| 17570524 | COMPOSITIONS DERIVED FROM HUMAN AMNION CELLS & RELATED METHODS | Final Rejection | AXOLOTL BIOLOGIX, INC |
| 17458206 | USE OF APOPTOTIC CELLS EX VIVO TO GENERATE REGULATORY T CELLS | Final Rejection | Therakos Development Limited |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy